{"id":"W4379282289","doi":"10.1200/jco.2023.41.16_suppl.4132","title":"ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Initial safety analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Nuclear medicine; Adverse effect; Internal medicine; Somatostatin receptor 2; Somatostatin receptor; Somatostatin; Radionuclide therapy; Toxicity; Pharmacokinetics; Gastroenterology; Oncology; Pharmacology; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002911349,0.000478416,0.003922831,0.001733247,0.0001057367,0.00005994109,0.0004606986,0.00008219595,0.0004184422],"category_scores_gemma":[0.009610389,0.0003794965,0.001175829,0.002080709,0.0007366185,0.0005800776,0.0001963567,0.002265413,0.00002821802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002336324,"about_ca_system_score_gemma":0.001909693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004887136,"about_ca_topic_score_gemma":0.00008399321,"domain_scores_codex":[0.9876497,0.003106826,0.006082822,0.000655488,0.001404638,0.001100524],"domain_scores_gemma":[0.9896353,0.004678266,0.003694556,0.0005485786,0.0006410179,0.0008022391],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5116776,0.009312959,0.3231695,0.0003461694,0.001994664,0.04411718,0.0003881089,0.001553587,0.003154546,0.00000973182,0.001962115,0.1023139],"study_design_scores_gemma":[0.5697376,0.1285886,0.2434825,0.002379813,0.002957916,0.006667673,0.004633601,0.01388195,0.007689688,0.000398675,0.0185409,0.00104105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941475,0.0002213473,0.00009899463,0.003654512,0.000549808,0.001040939,0.00007012815,0.00006241354,0.0001543595],"genre_scores_gemma":[0.9932307,0.001387666,0.003271472,0.0005236213,0.001234965,0.00005960566,0.00008797844,0.0000850888,0.0001189115],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1192757,"threshold_uncertainty_score":0.9998657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1190048836507754,"score_gpt":0.4956917116793705,"score_spread":0.3766868280285951,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}